Generation of a homozygous TIGIT gene knockout (TIGIT(-/-)) human iPSC line (MUSIi001-A-3) using CRISPR/Cas9 system
Summary
Adoptive cell therapy for solid cancers involves enhancing and reinfusing immune cells to target tumor cells. The advancement of induced pluripotent stem cell technology enables the generation of immune cell products like T and NK cells for ACT. However, the expression of inhibitory receptors, such as TIGIT, may limit the functionality of these immune effector cells. In this study, we generated a homozygousTIGITgene knockout iPSC line to potentially prevent inhibitory signaling and exhaustion, thereby creating potent "off-the-shelf" immune cell products for cellular immunotherapy applications. This approach could offer a new frontier in the fight against solid tumors. Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
| Authors | Srisantitham J, Suwanpitak S, Thongsin N, Wattanapanitch M |
|---|---|
| Journal | Stem cell research |
| Publication Date | 2024 Dec;81:103601 |
| PubMed | 39476616 |
| DOI | 10.1016/j.scr.2024.103601 |